Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...

The subcutaneous administration of granisetron, an antiemetic pharmaceutical drug (suitable for control of vomiting), achieves similar blood concentrations to those administered intravenously. This ...

For patients with metastatic non–small cell lung cancer (NSCLC), subcutaneous (SC) administration of pembrolizumab works just as well as standard intravenous (IV) administration, phase 3 data ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...

Boruzu is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma. The FDA has approved Amneal ...

- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...

The gastric hormone ghrelin appears a useful agent to stimulate food intake in people with anorexia of illness. The loss of ghrelin's acyl group renders it inactive, thus it has been thought that ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Radiation Therapy for Squamous Cell Carcinoma of the Tonsillar Region: A Preferred Alternative to Surgery? PURPOSE: Amifostine (WR-2721) is an impotant cytoprotective agent. Although intravenous ...

Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), ...